- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Key RRMM-Related Takeaways from ASH 2023
Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
EP: 1.Unmet Needs and Treatment Approaches in Newly Diagnosed Multiple Myeloma
EP: 2.ASH 2023: PERSEUS Trial Overview
EP: 3.Considerations for Combination Therapy and MRD Testing in Newly Diagnosed Multiple Myeloma Patients
EP: 4.ASH 2023: Analyzing IsKia Trial
EP: 5.Examining Data from MonumenTAL-2 Study
EP: 6.Optimizing Bispecific Use in Multiple Myeloma Treatment
EP: 7.Navigating Impact of RRMM Treatment on Patient Quality of Life
EP: 8.Key RRMM-Related Takeaways from ASH 2023
This is a video synopsis/summary of a Post Conference Perspectives featuring Rafael Fonseca, MD.
An update was provided on sonrotoclax, a next-generation BCL2 inhibitor that may exceed venetoclax potency. Early data combining sonrotoclax and dexamethasone shows efficacy in relapsed/refractory multiple myeloma with a favorable toxicity profile. This is an exciting addition given challenges gaining regulatory approval for venetoclax despite its clear value. While this translocation in level 14 imperfectly predicts response, other biomarkers like BCL2 expression levels or BCL2/BCL2L1 ratios could identify responsive patients for BCL2 inhibition. Fonesca hopes sonrotoclax progresses to become the first FDA-approved drug in this class for myeloma.
Looking ahead, 2024 may reveal more around small molecules like BCL2 inhibitors and next-generation cereblon-binding agents. Earlier chimeric antigen receptor T-cell and bispecific antibody data could emerge, potentially transforming outcomes when combined. The recent promising data also warrants follow-up. Fonseca believes properly combining these modalities can achieve high minimal residual disease negativity rates and long-term disease control. While myeloma remains incurable, glimpses of potential cures are being seen that bring hope for the future.
Video synopsis is AI-generated and reviewed by AJMC® editorial staff.
Lp(a) and Getting a Head Start Against Heart Disease: Jeremy Wigginton, MD
April 8th 2025Lipoprotein a (Lp[a]) is a valuable tool for assessing a patient's risk of cardiovascular disease, which can facilitate earlier intervention efforts and reduce health care costs, argued Jeremy Wigginton, MD.
Read More
Worse CTD-PAH Prognosis Seen With Higher HFA-PEFF Score
April 8th 2025The findings from this single-center retrospective study compare outcomes between 2 groups of patients living with connective tissue disease–associated pulmonary arterial hypertension (CTD-PAH) stratified by their Heart Failure Association–preserved ejection fraction (HFA-PEFF) algorithm score.
Read More
Guselkumab Shows Sustained Efficacy in Phase 3b APEX Study for Active PsA
April 8th 2025Long-term extension analysis of the phase 3b APEX study (NCT04882098) through 3 years of treatment will further assess the sustained efficacy of guselkumab (Tremfya; Johnson & Johnson) in limiting structural damage in patients with active psoriatic arthritis (PsA).
Read More
